Compare · MNMD vs RGC
MNMD vs RGC
Side-by-side comparison of Mind Medicine (MindMed) Inc. (MNMD) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNMD and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $9.88B, about 22.6x MNMD ($438.1M).
- Over the past year, MNMD is up 93.2% and RGC is up 25.1% - MNMD leads by 68.1 points.
- RGC has hit the wire 6 times in the past 4 weeks while MNMD has been quiet.
- MNMD has more recent analyst coverage (16 ratings vs 0 for RGC).
PerformanceMNMD+93.24%RGC+22.13%
2025-06-09+0.00%2026-01-14
- Company
- Mind Medicine (MindMed) Inc.
- Regencell Bioscience Holdings Limited
- Price
- $15.01+0.84%
- $20.09-9.50%
- Market cap
- $438.1M
- $9.88B
- 1M return
- +19.56%
- -27.34%
- 1Y return
- +93.24%
- +25.09%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 6
- Recent ratings
- 16
- 0
MNMD
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest MNMD
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)
- Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel sold $73,623 worth of shares (5,600 units at $13.15), decreasing direct ownership by 1% to 425,025 units (SEC Form 4)
- SEC Form 144 filed by Mind Medicine (MindMed) Inc.
- MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
- MindMed Announces New Employee Inducement Grant
- MindMed Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.
- Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Latest RGC
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited